| payload |
{"created_at":"2026-04-16T22:10:50.304 {"created_at":"2026-04-16T22:10:50.304260+00:00","signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/stock-market-today-april-16-hims-hers-health-jumps-fda-review-compounded-peptide-therapies","value":{"fp":"9337d97b8cc01d92","kind":"unusual_volume","published_at":"2026-04-16T21:17:04+00:00","source":"Nasdaq Markets","summary":"Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as investors reacted to the FDA\u2019s decision to review compounded peptide therapies. T","tickers":[],"title":"Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies","url":"https://www.nasdaq.com/articles/stock-market-today-april-16-hims-hers-health-jumps-fda-review-compounded-peptide-therapies"}}... |